{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T16:18:37Z","timestamp":1777652317551,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ejphar.2022.174902","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T11:25:52Z","timestamp":1648466752000},"page":"174902","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review"],"prefix":"10.1016","volume":"922","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5528-0658","authenticated-orcid":false,"given":"J\u00e9ssica Barreto Ribeiro","family":"dos Santos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2550-7249","authenticated-orcid":false,"given":"Michael Ruberson Ribeiro","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ejphar.2022.174902_bib1","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/head.14153","article-title":"The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice","volume":"61","author":"Ailani","year":"2021","journal-title":"Headache"},{"issue":"8","key":"10.1016\/j.ejphar.2022.174902_bib2","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1056\/NEJMoa2035908","article-title":"ADVANCE study group. Atogepant for the preventive treatment of migraine","volume":"385","author":"Ailani","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ejphar.2022.174902_bib3","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcph.1610","article-title":"Atogepant has No clinically relevant effects on the pharmacokinetics of an Ethinyl estradiol\/levonorgestrel oral contraceptive in healthy female participants","volume":"60","author":"Ankrom","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.174902_bib4","series-title":"Assignee. Piperidinone Carboxamide Azaindane CGRP Receptor Antagonists","author":"Bell","year":"2015"},{"issue":"2","key":"10.1016\/j.ejphar.2022.174902_bib5","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nchem.1243","article-title":"Quantifying the chemical beauty of drugs","volume":"4","author":"Bickerton","year":"2012","journal-title":"Nat. Chem."},{"issue":"4","key":"10.1016\/j.ejphar.2022.174902_bib6","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/head.12055","article-title":"Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II)","volume":"53","author":"Blumenfeld","year":"2013","journal-title":"Headache"},{"issue":"7","key":"10.1016\/j.ejphar.2022.174902_bib7","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/cpdd.916","article-title":"Single-dose pharmacokinetics and safety of atogepant in adults with hepatic impairment: results from an open-label, phase 1 trial","volume":"10","author":"Boinpally","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"6","key":"10.1016\/j.ejphar.2022.174902_bib8","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s40261-021-01034-5","article-title":"Evaluation of the pharmacokinetic interaction and safety of atogepant Co-administered with acetaminophen or naproxen in healthy participants: a randomized trial","volume":"41","author":"Boinpally","year":"2021","journal-title":"Clin. Drug Invest."},{"issue":"9","key":"10.1016\/j.ejphar.2022.174902_bib9","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/cpdd.940","article-title":"A single supratherapeutic dose of atogepant does not affect cardiac repolarization in healthy adults: results from a randomized, single-dose, phase 1 crossover trial","volume":"10","author":"Boinpally","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"11","key":"10.1016\/j.ejphar.2022.174902_bib10","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1016\/j.bmcl.2013.04.012","volume":"23","author":"Chaturvedula","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"4","key":"10.1016\/j.ejphar.2022.174902_bib11","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1021\/jp310798d","article-title":"Engagement of CF3 group in N-H\u00b7\u00b7\u00b7F-C hydrogen bond in the solution state: NMR spectroscopy and MD simulation studies","volume":"117","author":"Chaudhari","year":"2013","journal-title":"J. Phys. Chem. B"},{"issue":"4","key":"10.1016\/j.ejphar.2022.174902_bib12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1358\/dof.2021.46.4.3238324","article-title":"Calcitonin gene-related peptide (CGRP) receptor antagonist, Treatment of migraine","volume":"46","author":"Cipolla","year":"2021","journal-title":"Drugs Future"},{"key":"10.1016\/j.ejphar.2022.174902_bib14","first-page":"1","article-title":"A phase 1 randomized study of hemodynamic effects and pharmacokinetic interactions during concomitant use of rimegepant and sumatriptan in healthy adults","volume":"4","author":"Croop","year":"2021","journal-title":"Cephal Rep"},{"issue":"10268","key":"10.1016\/j.ejphar.2022.174902_bib15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","article-title":"Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial","volume":"397","author":"Croop","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2022.174902_bib16","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"issue":"35","key":"10.1016\/j.ejphar.2022.174902_bib17","doi-asserted-by":"crossref","first-page":"11058","DOI":"10.1002\/chem.201402858","article-title":"Fluorine as a hydrogen-bond acceptor: experimental evidence and computational calculations","volume":"20","author":"Dalvit","year":"2014","journal-title":"Chemistry"},{"issue":"1","key":"10.1016\/j.ejphar.2022.174902_bib18","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s10194-017-0807-1","article-title":"Blocking CGRP in migraine patients - a review of pros and cons","volume":"18","author":"Deen","year":"2017","journal-title":"J. Headache Pain"},{"issue":"16","key":"10.1016\/j.ejphar.2022.174902_bib19","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.1021\/jm800546t","volume":"51","author":"Degnan","year":"2008","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejphar.2022.174902_bib20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s10194-019-0974-3","article-title":"Therapeutic novelties in migraine: new drugs, new hope?","volume":"20","author":"Do","year":"2019","journal-title":"J. Headache Pain"},{"issue":"3","key":"10.1016\/j.ejphar.2022.174902_bib21","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/0333102418821662","article-title":"CGRP ligand and receptor monoclonal antibodies for migraine prevention: evidence review and clinical implications","volume":"39","author":"Dodick","year":"2019","journal-title":"Cephalalgia"},{"issue":"13","key":"10.1016\/j.ejphar.2022.174902_bib22","doi-asserted-by":"crossref","first-page":"6600","DOI":"10.1021\/acs.jmedchem.9b01810","article-title":"Blocking the CGRP pathway for acute and preventive treatment of migraine: the evolution of success","volume":"63","author":"Dubowchik","year":"2020","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejphar.2022.174902_bib27","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/bph.15585","article-title":"CGRP receptor antagonists for migraine. Are they also AMY1 receptor antagonists?","volume":"179","author":"Garelja","year":"2022","journal-title":"Br. J. Pharmacol."},{"issue":"10258","key":"10.1016\/j.ejphar.2022.174902_bib28","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","year":"2020","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ejphar.2022.174902_bib29","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1474-4422(20)30234-9","article-title":"Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b\/3 trial","volume":"19","author":"Goadsby","year":"2020","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.ejphar.2022.174902_bib30","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/head.13510","article-title":"Calcitonin gene-related peptide modulators - the history and renaissance of a new migraine drug class","volume":"59","author":"Hargreaves","year":"2019","journal-title":"Headache"},{"issue":"1","key":"10.1016\/j.ejphar.2022.174902_bib31","first-page":"1","article-title":"The international classification of headache disorders","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1016\/j.ejphar.2022.174902_bib32","first-page":"22","article-title":"Systematic review of migraine prophylaxis adherence and persistence","volume":"20","author":"Hepp","year":"2014","journal-title":"J. Manag. Care Pharm."},{"issue":"6","key":"10.1016\/j.ejphar.2022.174902_bib33","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1177\/0333102411398399","article-title":"Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine","volume":"31","author":"Hewitt","year":"2011","journal-title":"Cephalalgia"},{"issue":"11","key":"10.1016\/j.ejphar.2022.174902_bib34","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1212\/WNL.0000000000000771","article-title":"Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention","volume":"83","author":"Ho","year":"2014","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ejphar.2022.174902_bib35","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1177\/0333102415584308","article-title":"Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine","volume":"36","author":"Ho","year":"2016","journal-title":"Cephalalgia"},{"issue":"10","key":"10.1016\/j.ejphar.2022.174902_bib36","doi-asserted-by":"crossref","first-page":"5209","DOI":"10.1007\/s12325-021-01897-2","article-title":"Mapping migraine-specific quality of life to health state utilities in patients receiving rimegepant","volume":"38","author":"Johnston","year":"2021","journal-title":"Adv. Ther."},{"issue":"3","key":"10.1016\/j.ejphar.2022.174902_bib37","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0196-9781(00)00160-1","article-title":"Digestive motor effects and vascular actions of CGRP in dog are expressed by different receptor subtypes","volume":"21","author":"L'Heureux","year":"2000","journal-title":"Peptides"},{"issue":"5","key":"10.1016\/j.ejphar.2022.174902_bib38","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","article-title":"Migraine prevalence, disease burden, and the need for preventive therapy","volume":"68","author":"Lipton","year":"2007","journal-title":"Neurology"},{"issue":"23","key":"10.1016\/j.ejphar.2022.174902_bib39","doi-asserted-by":"crossref","first-page":"10644","DOI":"10.1021\/jm3013147","volume":"55","author":"Luo","year":"2012","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejphar.2022.174902_bib40","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/head.13498","article-title":"Patient preferences for preventive migraine treatments: a discrete-choice experiment","volume":"59","author":"Mansfield","year":"2019","journal-title":"Headache"},{"issue":"5","key":"10.1016\/j.ejphar.2022.174902_bib41","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1358\/dof.2020.45.5.3123467","article-title":"Atogepant.Calcitonin gene-related peptide (CGRP) receptor antagonist, Preventive treatment of migraine","volume":"45","author":"Martelletti","year":"2020","journal-title":"Drugs Future"},{"issue":"2","key":"10.1016\/j.ejphar.2022.174902_bib42","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/cts.12917","article-title":"Atogepant is not associated with clinically meaningful alanine aminotransferase elevations in healthy adults","volume":"14","author":"Min","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"7","key":"10.1016\/j.ejphar.2022.174902_bib43","article-title":"Small-molecule CGRP receptor antagonists: a new approach to the acute and preventive treatment of migraine","author":"Moreno-Ajona","year":"2020","journal-title":"Medicine in Drug Discovery"},{"issue":"4","key":"10.1016\/j.ejphar.2022.174902_bib44","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/cpt.564","article-title":"Drug-induced liver injury: advances in mechanistic understanding that will inform risk management","volume":"101","author":"Mosedale","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2022.174902_bib46","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3389\/fphar.2020.01240","article-title":"Antagonism of CGRP signaling by rimegepant at two receptors","volume":"11","author":"Pan","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"2 Suppl. 2","key":"10.1016\/j.ejphar.2022.174902_bib47","first-page":"S1","article-title":"Canadian headache society prophylactic guidelines development group. Canadian headache society guideline for migraine prophylaxis","volume":"39","author":"Pringsheim","year":"2012","journal-title":"Can. J. Neurol. Sci."},{"issue":"15","key":"10.1016\/j.ejphar.2022.174902_bib49","article-title":"Mass balance and metabolism of carbon-14 atogepant in healthy male participants","volume":"96","author":"Rowe","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2022.174902_bib50","article-title":"Time course of efficacy of atogepant for the preventive treatment of migraine: results from the randomized, double-blind ADVANCE trial","author":"Schwedt","year":"2021","journal-title":"Cephalalgia"},{"issue":"17","key":"10.1016\/j.ejphar.2022.174902_bib51","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","volume":"78","author":"Silberstein","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ejphar.2022.174902_bib52","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/toxsci\/kfaa093","article-title":"Mechanistic investigations support liver safety of ubrogepant","volume":"177","author":"Smith","year":"2020","journal-title":"Toxicol. Sci."},{"issue":"1","key":"10.1016\/j.ejphar.2022.174902_bib53","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","article-title":"Lifting the Burden: the Global Campaign against Headache. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019","volume":"21","author":"Steiner","year":"2020","journal-title":"J. Headache Pain"},{"issue":"34","key":"10.1016\/j.ejphar.2022.174902_bib54","doi-asserted-by":"crossref","first-page":"8764","DOI":"10.1002\/chem.202100301","article-title":"Hydrogen bond acceptor propensity of different fluorine atom types: an analysis of experimentally and computationally derived parameters","volume":"27","author":"Vulpetti","year":"2021","journal-title":"Chemistry"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922001637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922001637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T23:03:57Z","timestamp":1757977437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299922001637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":47,"alternative-id":["S0014299922001637"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.174902","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.174902","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"174902"}}